
Evolus, Inc. – NASDAQ:EOLS
Evolus stock price today
Evolus stock price monthly change
Evolus stock price quarterly change
Evolus stock price yearly change
Evolus key metrics
Market Cap | 694.00M |
Enterprise value | 20.96M |
P/E | -6.25 |
EV/Sales | 0.14 |
EV/EBITDA | -0.34 |
Price/Sales | N/A |
Price/Book | 0.02 |
PEG ratio | 0.15 |
EPS | -1.05 |
Revenue | 219.00M |
EBITDA | -37.75M |
Income | -60.00M |
Revenue Q/Q | 42.21% |
Revenue Y/Y | 40.00% |
Profit margin | -50% |
Oper. margin | -38.74% |
Gross margin | 62.4% |
EBIT margin | -38.74% |
EBITDA margin | -17.24% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEvolus stock price history
Evolus stock forecast
Evolus financial statements
Jun 2023 | 49.34M | -18.14M | -36.76% |
---|---|---|---|
Sep 2023 | 49.32M | -16.92M | -34.31% |
Dec 2023 | 60.99M | -11.83M | -19.4% |
Mar 2024 | 59.33M | -13.10M | -22.09% |
Mar 2024 | 59.33M | -13.10M | -22.09% |
---|---|---|---|
Sep 2025 | 132.55M | 1.60M | 1.21% |
Oct 2025 | 91.2M | 2.41M | 2.64% |
Dec 2025 | 99.8M | 8.64M | 8.66% |
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 168983000 | 175.94M | 104.12% |
---|---|---|---|
Sep 2023 | 167971000 | 187.33M | 111.53% |
Dec 2023 | 188998000 | 209.68M | 110.95% |
Mar 2024 | 226176000 | 207.73M | 91.85% |
Jun 2023 | -13.31M | -216K | 23.82M |
---|---|---|---|
Sep 2023 | -34.82M | -1.26M | 21.11M |
Dec 2023 | 813K | -361K | 23.52M |
Mar 2024 | -10.61M | -797K | 45.66M |
Evolus alternative data
Aug 2023 | 224 |
---|---|
Sep 2023 | 215 |
Oct 2023 | 215 |
Nov 2023 | 215 |
Dec 2023 | 246 |
Jan 2024 | 246 |
Feb 2024 | 246 |
Mar 2024 | 273 |
Apr 2024 | 273 |
May 2024 | 273 |
Jun 2024 | 279 |
Jul 2024 | 279 |
Evolus other data
Period | Buy | Sel |
---|---|---|
Jan 2024 | 0 | 11931 |
Feb 2024 | 0 | 11348 |
Mar 2024 | 0 | 136077 |
May 2024 | 0 | 60276 |
Jun 2024 | 0 | 478932 |
Aug 2024 | 0 | 5631 |
Sep 2024 | 0 | 3276 |
Dec 2024 | 0 | 14340 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Sale | AVELAR RUI officer: See Remarks | Common Stock | 2,252 | $10.85 | $24,439 | ||
Sale | BEAVER SANDRA officer: Chief Financial Officer | Common Stock | 1,586 | $10.85 | $17,211 | ||
Sale | MOATAZEDI DAVID director, officer.. | Common Stock | 10,502 | $10.85 | $113,968 | ||
Sale | BEAVER SANDRA officer: Chief Financial Officer | Common Stock | 3,276 | $14.98 | $49,074 | ||
Sale | YAMAGISHI-DRESSLER TOMOKO officer: Chief Marketing Officer | Common Stock | 5,631 | $15.85 | $89,251 | ||
Option | MOATAZEDI DAVID director, officer.. | Stock Option (Right to Buy) | 175,940 | $7.28 | $1,280,843 | ||
Option | MOATAZEDI DAVID director, officer.. | Common Stock | 175,940 | $7.28 | $1,280,843 | ||
Sale | MOATAZEDI DAVID director, officer.. | Common Stock | 175,940 | $12.59 | $2,214,557 | ||
Option | MOATAZEDI DAVID director, officer.. | Common Stock | 155,278 | $5.46 | $847,818 | ||
Sale | MOATAZEDI DAVID director, officer.. | Common Stock | 155,278 | $12.92 | $2,006,502 |
Quarter | Transcript |
---|---|
Q1 2024 7 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 7 Mar 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 2 Aug 2023 | Q2 2023 Earnings Call Transcript |
Insider | Compensation |
---|---|
Mr. David Moatazedi (1978) Pres, Chief Executive Officer & Director | $1,250,000 |
Ms. Lauren P. Silvernail (1958) Chief Financial Officer & Executive Vice President of Corporation Devel. | $633,180 |
Dr. Rui Avelar Dip.SportMed, M.D., C.CFP (1962) Chief Medical Officer and Head of R&D | $631,260 |
Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy
Evolus: Still Bullish, But Business Faces Tricky Challenges In '25
Evolus: Chiseling Away At The Aesthetic Market
Evolus: Gaining Market Share
Evolus: Botox Copy Cat In A Challenging Aesthetic Market
Evolus: Capitalizing On The Growth Of Aesthetics Market
Evolus: Extra Strength Dose Data Provides Additional Offering Expansion For Jeuveau
Revance Therapeutics: More Risk To Sept. 8 PDUFA Than It Seems
-
What's the price of Evolus stock today?
One share of Evolus stock can currently be purchased for approximately $7.1.
-
When is Evolus's next earnings date?
Unfortunately, Evolus's (EOLS) next earnings date is currently unknown.
-
Does Evolus pay dividends?
No, Evolus does not pay dividends.
-
How much money does Evolus make?
Evolus has a market capitalization of 694.00M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 35.98% to 202.09M US dollars.
-
What is Evolus's stock symbol?
Evolus, Inc. is traded on the NASDAQ under the ticker symbol "EOLS".
-
What is Evolus's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Evolus?
Shares of Evolus can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Evolus's key executives?
Evolus's management team includes the following people:
- Mr. David Moatazedi Pres, Chief Executive Officer & Director(age: 47, pay: $1,250,000)
- Ms. Lauren P. Silvernail Chief Financial Officer & Executive Vice President of Corporation Devel.(age: 67, pay: $633,180)
- Dr. Rui Avelar Dip.SportMed, M.D., C.CFP Chief Medical Officer and Head of R&D(age: 63, pay: $631,260)
-
How many employees does Evolus have?
As Jul 2024, Evolus employs 279 workers, which is 2% more then previous quarter.
-
When Evolus went public?
Evolus, Inc. is publicly traded company for more then 7 years since IPO on 8 Feb 2018.
-
What is Evolus's official website?
The official website for Evolus is evolus.com.
-
Where are Evolus's headquarters?
Evolus is headquartered at 520 Newport Center Drive, Newport Beach, CA.
-
How can i contact Evolus?
Evolus's mailing address is 520 Newport Center Drive, Newport Beach, CA and company can be reached via phone at +94 92844555.
Evolus company profile:

Evolus, Inc.
evolus.comNASDAQ
322
Drug Manufacturers - Specialty & Generic
Healthcare
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Newport Beach, CA 92660
CIK: 0001570562
ISIN: US30052C1071
CUSIP: 30052C107